Tudor Investment Corp’s CytomX Therapeutics CTMX Stock Holding History

Tudor Investment Corp’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-43,865	Closed	-$95.6K	–	2393
2024 Q1	$95.6K	Sell	43,865 -865	-2%	-$1.6K	﹤0.01%	2095
2023 Q4	$69.3K	Hold	44,730	–	–	﹤0.01%	2258
2023 Q3	$57.7K	Hold	44,730	–	–	﹤0.01%	2173
2023 Q2	$76.9K	Hold	44,730	–	–	﹤0.01%	2310
2023 Q1	$68K	Sell	44,730 -118,267	-73%	-$267K	﹤0.01%	2275
2022 Q4	$261K	Hold	162,997	–	–	0.01%	1997
2022 Q3	$236K	Hold	162,997	–	–	0.01%	1955
2022 Q2	$298K	Hold	162,997	–	–	0.01%	1566
2022 Q1	$435K	Buy	+162,997	New	+$626K	0.01%	1348
2021 Q1	–	Sell	-51,873	Closed	-$340K	–	1607
2020 Q4	$340K	Sell	51,873 -47,068	-48%	-$336K	0.01%	1081
2020 Q3	$658K	Buy	98,941 +74,370	+303%	+$552K	0.03%	717
2020 Q2	$205K	Sell	24,571 -18,720	-43%	-$174K	0.01%	1021
2020 Q1	$332K	Sell	43,291 -35,488	-45%	-$247K	0.03%	655
2019 Q4	$655K	Buy	+78,779	New	+$532K	0.03%	639

Other funds holding CTMX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Tudor Investment Corp's CTMX Position: Q2 2024 in Review

Tudor Investment Corp sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 43,865 shares — an estimated $95.6K sold.

Tudor Investment Corp first reported a position in CTMX in Q4 2019 and held it in 14 quarters. The position peaked at $658K in Q3 2020. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

Tudor Investment Corp reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
Tudor Investment Corp sold 43,865 CytomX Therapeutics shares in Q2 2024, an estimated $95.6K.
Tudor Investment Corp first reported a position in CytomX Therapeutics in Q4 2019 and held it in 14 quarters.
Tudor Investment Corp's CytomX Therapeutics position peaked at $658K in Q3 2020.
74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on Tudor Investment Corp's 13F filing for Q2 2024, filed 14 Aug 2024.